Primary sclerosing cholangitis: Diagnosis and management

被引：35

作者：

Charatcharoenwitthaya P. ^{[1
]}

Lindor K.D. ^{[1
]}

机构：

[1] Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, MN 55905, 200 First Street, SW

来源：

Current Gastroenterology Reports | 2006年 / 8卷 / 1期

关键词：

Liver Transplantation; Cholangiocarcinoma; Primary Biliary Cirrhosis; Primary Sclerosing Cholangitis; Sclerosing Cholangitis;

D O I：

10.1007/s11894-006-0067-8

中图分类号：

学科分类号：

摘要：

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease caused by progressive inflammatory destruction of intrahepatic and extrahepatic bile ducts, and ultimately cirrhosis. PSC occurs primarily in patients with underlying ulcerative colitis and affects primarily young to middle-aged men. PSC is believed to be an autoimmune disease mediated by immune dysregulation in patients with genetic susceptibility. One possible mechanism for the development of PSC is the homing of memory lymphocytes to the biliary tract. Cholangiography is the gold standard for diagnosis of PSC. The typical radiologic findings include multifocal strictures and dilation involving the intrahepatic or extrahepatic biliary tract, or both. Although no medical therapy has proved beneficial, a variety of agents have been tested, some of which appear promising and deserve further study. High-dose ursodeoxycholic acid may have benefit in slowing disease progression; a multicenter placebo-controlled trial is ongoing. Liver transplantation is a good option for patients with advanced PSC, although the disease can recur after successful transplantation. Copyright © 2006 by Current Science Inc.

引用

页码：75 / 82

页数：7

共 75 条

[1]

Boberg K.M., Aadland B., Jahnsen J., Et al., Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population, Scand J Gastroenterol, 33, pp. 99-103, (1998)

[2]

Bambha K., Kim W.R., Talwalkar J., Et al., Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community, Gastroenterology, 125, pp. 1364-1369, (2003)

[3]

Kingham J.G., Kochar N., Gravenor M.B., Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom, Gastroenterology, 126, pp. 1929-1930, (2004)

[4]

Bergquist A., Lindberg G., Saarinen S., Et al., Increased prevalence of primary sclerosing cholangitis among first-degree relatives, J Hepatol, 42, pp. 252-256, (2005)

[5]

Lawson A., West J., Aithal G.P., Et al., Autoimmune cholestatic liver disease in people with coeliac disease: A population-based study of their association, Aliment Pharmacol Ther, 21, pp. 401-405, (2005)

[6]

Talwalkar J.A., Lindor K.D., Primary sclerosing cholangitis, Inflamm Bowel Dis, 11, pp. 62-72, (2005)

[7]

Aoki C.A., Bowlus C.L., Gershwin M.E., The immunobiology of primary sclerosing cholangitis, Autoimmun Rev, 4, pp. 137-143, (2005)

[8]

Feldstein A.E., Perrault J., El-Youssif M., Et al., Primary sclerosing cholangitis in children: A long-term follow-up study, Hepatology, 38, pp. 210-217, (2003)

[9]

Nakazawa T., Ohara H., Sano H., Et al., Cholangiography can discriminate sclerosing cholangitis with autoimmune pancreatitis from primary sclerosing cholangitis, Gastrointest Endosc, 60, pp. 937-944, (2004)

[10]

Resnick D., Krinsky G.A., Lavelle M.T., Et al., Do patients with primary sclerosing cholangitis have a greater frequency of pancreatic abnormalities at MRI than patients with other liver diseases?, J Comput Assist Tomogr, 26, pp. 994-999, (2002)

← 1 2 3 4 5 6 7 8 →